1Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population:Third Natio- nal Health and Nutrition Examination Survey [ J ]. Am J Kidney Dis, 2003,41 ( 1 ) : 1 - 12.
2Zhang L, Zhang P, Wang F,et al. Prevalence and factors associated with CKD : A population study from Beijing [ J ]. Ant J Kidney Dis, 2008,51 (3) :373 -384.
3Hewitson TD. Renal tubulointerstitial fibrosis:Common but never simple [J]. Am J Physiol Renal Physiol,2009,296 ( 6 ) : F1239 - F1244.
4Fogo AB. Progression versus regression of chronic kidney disease [ J ]. Nephrol Dial Transplant ,2006,21 (2) :281 - 284.
5Fioretto P, Steffes MW,Sutherland DE, et al. Reversal of lesions of dia- betic nephropathy after pancreas transplantation [ J ]. N Engl J Med, 1998,339(2) :69 -75.
6Rodriguez - hurbe B, Pons H, Herrera - Acosta J, et aL Role of immuno- competent cells in nonimmune renal diseases [ J ]. Kidney lnt, 2001,59 ( 5 ) : 1626 - 1640.
8Yuan HT, Li XE, Pitera JE, et al. Peritubular capillary loss after mouse acute nephrotoxicity correlates with down - regulation of vascular endothelial growth factor - A and hypoxia - inducible factor - 1 alpha [ J ]. Am J Pathol,2003,163 (6) :2289 - 2301.
9Daniel C. Blocking of angiotensin 11 is more than blocking of transfor- ming growth factor - β [ J ]. Kidney lnt, 2008,74 ( 5 ) : 551 - 553.
10Matsuo S, Lopez - Guisa JM, Cai X, et al. Multifunctionality of PAI- 1 in fibrogenesis: Evidence from obstructive nephropathy in PAI- 1 -overexpressing mice[J].Kidney lnt ,2005,67 (6) :2221 - 2238.
3Gyebi L, Soltani Z, Reisin E. Lipid nephrotoxicity: new concept for an old disease[J]. Curr Hypertens Rep, 2012, 14(2): 177-181.
4D'Agati VD, Fogo AB, Bruijn JA, et al. Pathological classification of focal segmental glomeruloscleresis: a working proposal[J]. Am J Kidney Dis, 2004, 43(2): 368-382.
5Saito T. Abnormal lipid metabolism and renal disorders[J]. Tohoku J Exp Med, 1997, 181(3): 321-337.
7Lee HS. Mechanismsand consequences of hypeariglycefdemia and cellular lipid accumulation in chronic kidney disease and metabolic syndromeS]. HistolHistopathol, 2011, 26(12): 1599- 1610.
8Contois JH, Warnick GR, Sniderman AD. Reliability of low- density lipoproteincholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement[J]. J Clin Lipidol, 2011, 5(4): 264-272.
9Sniderman AD, Islam S, Yusuf S, et al. Discordance analysis of Apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study[J]. Atherosclerosis, 2012, 225(2): 444-449.
10Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100[J]. Atherosclerosis, 1993, 104(1-2): 159-171.
